Amivantamab in Adenoid Cystic Carcinoma

Part of paid clinical trials in La Jolla, California.

Sponsor
Trisha Wise-Draper
Study ID
NCT05074940
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Salivary Gland Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Amivantamab — DRUG
    Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Study Details

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Key Dates

Start date
Aug 5, 2022
Status verified
May 2026
Primary completion
Mar 2, 2026
Completion
Aug 5, 2028

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Amivantamab
    Amivantamab weekly for the first cycle and biweekly thereafter.

Primary Outcome Measure

Overall Response Rate Measured by RECIST Criteria [ Time Frame: 2 years ]

Locations (5)

FacilityCityStateZIPSite coordinators
UC San Diego Moores Cancer CenterLa JollaCalifornia92093-
Dana Farber Cancer InstituteBostonMassachusetts02215-
Rogel Cancer Center - University of Michigan HealthAnn ArborMichigan48109-
Washington University - School of Medicine in St. LouisSt LouisMissouri63130-
University of Cincinnati Medical CenterCincinnatiOhio45219-

Related coverage on Hipa.ai

Find similar trials in La Jolla, CA

By research site
UC San Diego Moores Cancer Center· La Jolla, CADana Farber Cancer Institute· Boston, MARogel Cancer Center - University of Michigan Health· Ann Arbor, MIWashington University - School of Medicine in St. Louis· St Louis, MOUniversity of Cincinnati Medical Center· Cincinnati, OH

Related Studies